Lilly recently announced that its RET inhibitor, selpercatinib (loxo-292), has been granted priority review status by the U.S. FDA and is expected to accelerate its approval for the treatment of […]
The two branches of the immune system, innate and adaptive, work together within an intricate network in order to respond to infectious threats while not destroying healthy self-tissue. As previously discussed, the […]